Other Events ·
On August 11, 2026, Mereo BioPharma Group plc entered into an Option and License Agreement with Sentynl Therapeutics…
MREOMereo BioPharma Group plc
On August 11, 2026, Mereo BioPharma Group plc entered into an Option and License Agreement with Sentynl Therapeutics, Inc. for U.S. commercial rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Under the deal, Mereo retains global development leadership and rest-of-world commercial rights while granting Sentynl an option to acquire U.S. licensing rights. Upon exercise of the option, Mereo is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential regulatory and commercial milestones, and double-digit tiered royalties on U.S. net sales. The companies will collaborate during a short option period to refine the Phase 3 study design, with development potentially initiating in early 2027. Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases.